What is the appropriate next step in management for a solid pulmonary nodule that increased from 7 mm to 9 mm over three months and a new 8 mm ground‑glass nodule that was absent on the prior CT scan?

Immediate Tissue Diagnosis Required

Both nodules demand urgent evaluation with PET/CT, nonsurgical biopsy, and/or surgical resection—the solid nodule showing rapid growth (7→9 mm in 3 months) and the new 8 mm ground-glass nodule both represent high-risk features requiring definitive diagnosis rather than continued surveillance.

Rationale for Aggressive Management

The Growing Solid Nodule (7→9 mm in 3 months)

This nodule demonstrates documented growth over a short interval, which is a critical red flag. According to ACCP guidelines, any solid nodule >8 mm warrants consideration of PET/CT, nonsurgical biopsy, or surgical diagnosis 1. The growth pattern here is particularly concerning:

• Growth kinetics matter: The 2 mm increase over 3 months suggests a doubling time consistent with malignancy
• For solid nodules >6-8 mm with risk factors, guidelines recommend initial follow-up at 3-6 months, then 9-12 months 1
• However, documented growth changes everything—it elevates this from surveillance to active intervention

The 2013 ACCP guidelines specifically state that for solid nodules >8 mm, surgical diagnosis is suggested when clinical probability of malignancy is high (>65%), or when functional imaging shows intense hypermetabolism 1. Growth itself substantially increases malignancy probability.

The New 8 mm Ground-Glass Nodule

This is equally concerning because:

• New appearance of a ground-glass nodule ≥8 mm requires aggressive evaluation
• Pure ground-glass nodules >5 mm require annual surveillance for at least 3 years 1
• But the 8 mm size threshold is critical: ACCP guidelines note that early follow-up at 3 months may be indicated for nonsolid nodules >10 mm, followed by nonsurgical biopsy and/or surgical resection for nodules that persist 1
• Ground-glass nodules that grow or develop a solid component are often malignant, prompting further evaluation and/or consideration of resection 1

Recommended Management Algorithm

Step 1: Immediate Repeat CT (Within 1 Month)

• Obtain thin-section (≤1.5 mm) CT with noncontrast technique 2
• Assess both nodules for:
  • Exact size measurements (average of long and short axes)
  • Presence of any solid component in the ground-glass nodule
  • Morphologic features (spiculation, irregular borders)

Step 2: Risk Stratification

Calculate malignancy probability using validated models (Brock, Mayo Clinic, or similar) incorporating:

• Patient age and smoking history
• Nodule size and growth rate
• Upper lobe location (if applicable)
• Spiculation or irregular margins

Step 3: Definitive Diagnosis Based on Risk

If high probability (>60%):

• Proceed directly to surgical resection via minimally invasive thoracoscopy 1
• This provides both diagnosis and treatment

If moderate probability (10-60%):

• Option A: PET/CT for functional assessment 3
  • If intensely hypermetabolic → surgical resection
  • If negative or equivocal → nonsurgical biopsy
• Option B: Direct nonsurgical biopsy (bronchoscopy or transthoracic needle biopsy) 1
  • Choose based on nodule location and local expertise
  • Sensitivity 70-90% for lung cancer diagnosis 4

If low probability (<10%) but growth documented:

• Still pursue tissue diagnosis given the growth pattern
• Consider nonsurgical biopsy first to avoid unnecessary surgery

Critical Pitfalls to Avoid

1. Do not continue surveillance imaging alone: The combination of documented growth in one nodule and a new 8 mm ground-glass nodule has moved beyond the surveillance phase

2. Do not delay based on size alone: While the solid nodule is technically still ≤8 mm at 9 mm, the growth pattern is more important than absolute size

3. Do not treat these as independent findings: Multiple nodules require individual evaluation, but the presence of two concerning nodules increases overall cancer probability 1

4. Do not use PET for the ground-glass nodule characterization: PET has limited utility for pure ground-glass lesions and should not be used to characterize part-solid lesions where the solid component measures <8 mm 1

5. Avoid the "wait and see" trap: The 3-month interval has already demonstrated concerning behavior—further delay risks disease progression

Special Considerations

• If surgical risk is high: Nonsurgical biopsy becomes more important to establish diagnosis before committing to surgery 1
• Patient preferences matter: Fully informed patients may prefer definitive surgical diagnosis over staged approaches, especially given the concerning features 1
• Multidisciplinary discussion: Given the complexity of two concerning nodules, involve thoracic surgery, pulmonology, and radiology in decision-making 5

The Asian consensus guidelines similarly emphasize that solid nodules >6-8 mm in high-risk patients should be re-evaluated at 3 months, 6 months, 12 months, and then annually if stable 3. Your patient has already failed the "stable" criterion with documented growth, necessitating escalation to tissue diagnosis.